



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 65-236

Food and Drug Administration
Rockville MD 20857

DEC 8 2005

TEVA Pharmaceuticals USA
Attention: Philip Erickson, R.Ph.
Senior Director, Regulatory Affairs
1090 Horsham Road
P.O. Box 1090
North Wales, PA 19454

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated June 30, 2004, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Cefprozil for Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. We note that this product is subject to the exception provisions of Section 125(d)(2) of Title I of the Food and Drug Administration Modernization Act of 1997.

Reference is also made to your amendments dated September 17, 2004; and April 21, May 27, June 16, July 22, August 1, August 9, September 8, and November 30, 2005.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Cefprozil for Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Cefzil[®] for Oral Suspension, 125 mg/5 mL and 250 mg/5 mL, respectively, of Bristol Myers Squibb Company Pharmaceutical Research Institute). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.


Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Gary Buehler" with a stylized flourish at the end.

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research